Market Overview

Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018


Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the company will
host a conference call and live webcast on Tuesday, August 7, 2018 at
8:00 A.M. ET to report its second quarter 2018 financial results and to
discuss recent business updates.

The live webcast can be accessed on the investor page of Sage's website
The conference call can be accessed by dialing 1-866-450-8683 (toll-free
domestic) or 1-281-542-4847 (international) and using the conference ID
5396188. A replay of the webcast will be available on Sage's website
approximately two hours after the completion of the event and will be
archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering CNS disorders. Sage has a portfolio of novel
product candidates targeting critical CNS receptor systems, GABAA
and NMDA. Sage's lead program, a proprietary IV formulation of
brexanolone (SAGE-547), has completed Phase 3 clinical development for
postpartum depression and a New Drug Application is currently under
review with the U.S. Food and Drug Administration. Sage is developing
its next generation modulators, including SAGE-217 and SAGE-718, in
various CNS disorders. For more information, please visit

View Comments and Join the Discussion!